About Sun PharmaSun Pharmaceuticals was established by Mr. Dilip Shanghvi in 1983 in Vapi, Gujarat with five products to treat psychiatry ailments. Cardiology products were introduced in 1987 followed by gastroenterology products in 1989. Today, it is the largest chronic prescription company in India and a market leader in psychiatry, neurology, cardiology, orthopedics, ophthalmology, gastroenterology and nephrology. Over 72% of Sun Pharma sales are from markets outside India, primarily in States. US is the single largest market, accounting for about 50% turnover; in all, formulations or finished dosage forms, account for 93% of the turnover. Manufacturing is across 26 locations, including plants in US, Canada, Brazil, Mexico and Israel. In US, the company markets a large basket of generics, with a strong pipeline awaiting approval from the U.S. Food and Drug Administration (FDA). Sun Pharma was listed on the stock exchange in 1994 in an issue oversubscribed 55 times. The founding family continues to hold a majority stakein the company. Today Sun Pharma is the second largest and the most profitable pharmaceuticalcompany in India, as well as the largest pharmaceutical company by market capitalisation on the Indian exchanges. The 2014 acquisition of Ranbaxy has made the company the largest pharma company
You've reached the end of your free preview.
Want to read both pages?
Generic drug, Ranbaxy Laboratories, Sun Pharmaceutical Industries Ltd, Sun Pharma sales